Wolfe Research upgraded AbbVie Inc. The firm raised its rating to 'Outperform' from 'Peerperform'. It set a price target of $300.
Canada recommended reimbursement for AbbVie's migraine treatment, UBRELVY.
The company's key immunology drugs, Skyrizi and Rinvoq, continue to show strong sales and market-share gains.